A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Ofatumumab (Primary) ; Bendamustine
- Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Registrational; Therapeutic Use
- Acronyms COMPLEMENT A+B
- Sponsors GlaxoSmithKline; Novartis
- 12 Jan 2018 Planned End Date changed from 18 Jul 2023 to 20 Dec 2024.
- 30 Oct 2017 Planned primary completion date changed from 30 Aug 2017 to 17 Nov 2017.
- 25 May 2017 Planned primary completion date changed from 17 Apr 2017 to 30 Aug 2017.